Pyxis Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by Pyxis Oncology, Inc. on June 18, 2025. The meeting was conducted virtually via live audio webcast. As of the record date of April 21, 2025, there were 61,947,665 shares of common stock outstanding. A quorum was established with 43,996,450 shares present virtually, in person, or by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results rather than financial performance.
Material Changes and Voting Results
Two proposals were acted upon by stockholders:
- Proposal One: Election of Class I Directors
- Dr. Santhosh Palani, Ph.D., CFA: Elected with 22,056,449 votes For, 7,314,363 Withheld, and 14,625,638 Broker Non-Votes.
- Mr. Darren Cline: Elected with 22,028,914 votes For, 7,341,898 Withheld, and 14,625,638 Broker Non-Votes.
- Dr. Rachel Humphrey, M.D.: Elected with 21,357,102 votes For, 8,013,710 Withheld, and 14,625,638 Broker Non-Votes.
- All three directors will serve until the 2028 Annual Meeting.
- Proposal Two: Ratification of Independent Auditor
- Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes: 43,733,259 For, 233,563 Against, 29,628 Abstain, and 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of voting outcomes.
Key Facts for Investor Verification
- Confirmation of the new Class I Directors' tenure extending to the 2028 Annual Meeting.
- Verification of the significant number of Broker Non-Votes (14,625,638) on the director election proposals.
- Confirmation that Ernst & Young LLP has been ratified as the auditor for the fiscal year ending December 31, 2025.
- Review of the total shares outstanding (61,947,665) versus shares present at the meeting (43,996,450) to assess shareholder engagement levels.